Brian Kelley
Adjunct Assistant Professor
Department of Chemical & Biological Engineering
4 Colby Street, Medford, MA 02155

Biography:
Brian D. Kelley is the Director of Purification Process Development at Genetics Institute-Wyeth. He obtained his B.S. in Chemical Engineering from the University of Wisconsin-Madison in 1987, and his Ph.D. in Chemical Engineering from MIT in 1992. Since 1992, he has worked both at Genetics Institute (now Wyeth BioPharma) in the process development group, and as an adjunct faculty member of the Chemical & Biological Engineering Department at Tufts University, where he teaches two graduate classes each year on Principles of Cell and Microbe Cultivation, and Protein Purification.

Brian’s development group at Genetics Institute is responsible for development, validation, and technology transfer of chromatography and filtration steps for the production of recombinant therapeutic proteins derived from both mammalian and bacterial hosts. Brian has designed purification process steps for production of many proteins, and supported the production of Genetics Institute’s licensed products (Factor VIII, Factor IX, Interleukin-11, and ReFacto (a protein engineered variant of Factor VIII)). His interests include experimental design and other statistical methods in process development, filtration for cell and virus removal, ultrafiltration of protein solutions, and development of novel affinity chromatography ligands for protein purification. Brian’s graduate thesis work evaluated a liquid-liquid extraction technique for affinity purification of proteins using reversed micelles.

Brian has been active in the American Chemical Society’s Biotechnology division, chairing sessions on biopharmaceutical process validation at the national meeting since 1997. While in graduate school, he served as a technical coordinator for the Biotechnology Process Engineering Center, recruiting and communicating with industrial sponsors, and organizing annual symposia highlighting the BPEC group’s research. He was awarded both NSF and NIH graduate fellowships while at MIT. In 2001, he edited the Biochemical Engineering edition of Current Opinions in Biotechnology.

Publications, Books and Patents:
Charlebois T.S., O’Connell B.D., Adamson S.R., Brink-Nilsson H., Jernberg M., Eriksson B., Kelley B.D. (in press) Viral safety of B-domain deleted recombinant Factor VIII, Sem. Hematol.

Kelley B.D. (2001) Biochemical engineering: Bioprocessing of therapeutic proteins, Cur. Op. Biotechnol., 12, 173-174.

Yu J., Potter M.D., Kelley B.D., Deetz J.S., Booth J.E. (2001) Polypeptides for binding human factor VIII and fragments of human factor VIII, U.S. Patent #6,197,526.

Kelley B.D. (2000) Establishing process robustness through designed experiments, in Biopharmaceutical Process Validation, D. Zabriske, G. Sofer, ed., Marcel Dekker.

Kelley B.D. and Ramelmeier R.A., editors (1998) Validation of Biopharmaceutical Manufacturing Processes, ACS Symposium Series.